<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38662331</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns.</ArticleTitle><Pagination><StartPage>1127</StartPage><EndPage>1146</EndPage><MedlinePgn>1127-1146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-00965-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The delivery of COVID-19 vaccines was successful in reducing hospitalizations and mortality. However, emergence of the Omicron variant resulted in increased virus transmissibility. Consequently, booster vaccination programs were initiated to decrease the risk of severe disease and death among vulnerable members of the population. This study aimed to estimate the effects of the booster program and alternative vaccination strategies on morbidity and mortality due to COVID-19 in the UK.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A Susceptible-Exposed-Infectious-Recovered (SEIR) model was used to assess the impact of several vaccination strategies on severe outcomes associated with COVID-19, including hospitalizations, mortality, National Health Service (NHS) capacity quantified by hospital general ward and intensive care unit (ICU) bed days, and patient productivity. The model accounted for age-, risk- and immunity-based stratification of the UK population. Outcomes were evaluated over a 48-week time horizon from September 2022 to August 2023 considering the actual UK autumn 2022/spring 2023 booster campaigns and six counterfactual strategies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The model estimated that the autumn 2022/spring 2023 booster campaign resulted in a reduction of 18,921&#xa0;hospitalizations and 1463 deaths, compared with a no booster scenario. Utilization of hospital bed days due to COVID-19 decreased after the autumn 2022/spring 2023 booster campaign. Expanding the booster eligibility criteria and improving uptake improved all outcomes, including averting twice as many ICU admissions, preventing more than 20% additional deaths, and a sevenfold reduction in long COVID, compared with the autumn 2022/spring 2023 booster campaign. The number of productive days lost was reduced by fivefold indicating that vaccinating a wider population has a beneficial impact on the morbidities associated with COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our modelling demonstrates that the autumn 2022/spring 2023 booster campaign reduced COVID-19-associated morbidity and mortality. Booster campaigns with alternative eligibility criteria warrant consideration in the UK, given their potential to further reduce morbidity and mortality as future variants emerge.</AbstractText><CopyrightInformation>&#xa9; 2024. Pfizer Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pfizer Ltd, Tadworth, UK. diana.mendes@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machira Krishnan</LastName><ForeName>Sheeja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Esm&#xe9;</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padgett</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Cale</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research Ltd, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strain</LastName><ForeName>W David</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manca</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Senior HTA Advisor, York, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ustianowski</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Manchester University Foundation Trust, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butfield</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pfizer Ltd, Tadworth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pfizer Ltd, Tadworth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynard</LastName><ForeName>Charlie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pfizer Ltd, Tadworth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Inc, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Social and Economic Research and Policy, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Booster campaign</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Comorbidities</Keyword><Keyword MajorTopicYN="N">Healthcare resource use</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Diana Mendes, Jingyan Yang, Cale Harrison, Rebecca Butfield, Elizabeth Hamson, and Charlie Reynard are employees of Pfizer and may own stocks. Sheeja Machira Krishnan, Thomas Padgett, and Esm&#xe9; O&#x2019;Brien are employees of Health Economics and Outcomes Research Ltd, which received funding from Pfizer in relation to the study and in connection with the development of this manuscript. Cale Harrison was an employee of Health Economics and Outcomes Research Ltd at the time of study, received fees for consultancy, and is now an employee of Pfizer. Andrea Manca, Andrew Ustianowski, and W David Strain were paid consultants to Pfizer in relation to the study and in connection with the development of this manuscript. Andrew Ustianowski also received advisory board and/or speaker fees from Gilead Sciences, Merck/MSD, Valneva, GSK/ViiV, Sanofi, unrelated to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>12</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38662331</ArticleId><ArticleId IdType="pmc">PMC11098993</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-00965-8</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-00965-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183&#x2013;195. doi: 10.1016/S1473-3099(21)00648-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. 2022;53:101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. COVID-19 vaccine surveillance report published. 2021. https://www.gov.uk/government/news/covid-19-vaccine-surveillance-report-published. Accessed 05 Sep 2023.</Citation></Reference><Reference><Citation>GOV.UK. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022. 2021. https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022. Accessed 28 June 2023.</Citation></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303&#x2013;1312. doi: 10.1016/S0140-6736(22)00462-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00462-7</ArticleId><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924&#x2013;944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532&#x2013;1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK. COVID-19 vaccines for autumn 2022: JCVI advice, 15 August 2022 (updated 3 September 2022). 2022. https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022. Accessed 04 Jan 2023.</Citation></Reference><Reference><Citation>GOV.UK. JCVI statement on the COVID-19 vaccination programme for 2023: 8 Novemeber 2022. 2023. https://www.gov.uk/government/publications/covid-19-vaccination-programme-for-2023-jcvi-interim-advice-8-november-2022/jcvi-statement-on-the-covid-19-vaccination-programme-for-2023-8-november-2022. Accessed 28 June 2023.</Citation></Reference><Reference><Citation>GOV.UK. JCVI updated statement on the COVID-19 vaccination programme for autumn 2022. 2022. https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022. Accessed 28 June 2023.</Citation></Reference><Reference><Citation>GOV.UK. A guide to the COVID-19 spring booster 2023. 2023. https://www.gov.uk/government/publications/covid-19-vaccination-spring-booster-resources/a-guide-to-the-covid-19-spring-booster-2023. Accessed 08 Nov 2023.</Citation></Reference><Reference><Citation>Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603(7902):700&#x2013;705. doi: 10.1038/s41586-022-04462-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira IATM, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603(7902):706&#x2013;714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes D, Chapman R, Aruffo E, et al. Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. Expert Rev Vaccines. 2023;22(1):90&#x2013;103. doi: 10.1080/14760584.2023.2158816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2158816</ArticleId><ArticleId IdType="pubmed">36519401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes D, Chapman R, Gal P, et al. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021. J Med Econ. 2022;25(1):1039&#x2013;1050. doi: 10.1080/13696998.2022.2111935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2022.2111935</ArticleId><ArticleId IdType="pubmed">36097853</ArticleId></ArticleIdList></Reference><Reference><Citation>The R Project for Statistical Computing. https://www.r-project.org/. Accessed 25 July 2023.</Citation></Reference><Reference><Citation>Walker JL, Grint DJ, Strongman H, et al. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health. 2021;21(1):484. doi: 10.1186/s12889-021-10427-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-10427-2</ArticleId><ArticleId IdType="pmc">PMC7948667</ArticleId><ArticleId IdType="pubmed">33706738</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556&#x2013;567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):e74. doi: 10.1371/journal.pmed.0050074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0050074</ArticleId><ArticleId IdType="pmc">PMC2270306</ArticleId><ArticleId IdType="pubmed">18366252</ArticleId></ArticleIdList></Reference><Reference><Citation>Knock ES, Whittles LK, Lees JA, et al. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. Sci Transl Med. 2021;13(602):eabg4262. doi: 10.1126/scitranslmed.abg4262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abg4262</ArticleId><ArticleId IdType="pmc">PMC8432953</ArticleId><ArticleId IdType="pubmed">34158411</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Social Care. COVID-19 autumn 2023 booster programme impact assessment. June 2023. Report No. 9604. https://assets.publishing.service.gov.uk/media/650ade0f52e73c001254dc08/covid-19-autumn-2023-impact-assessment.pdf. Accessed 25 July 2023.</Citation></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Leisure time in the UK: 2015 (2017). https://www.ons.gov.uk/economy/nationalaccounts/satelliteaccounts/articles/leisuretimeintheuk/2015. Accessed 25 July 2023.</Citation></Reference><Reference><Citation>Office for National Statistics. Employment, unemployment and economic inactivity by age group (seasonally adjusted). 2023. https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/datasets/employmentunemploymentandeconomicinactivitybyagegroupseasonallyadjusteda05sa. Accessed 25 July 2023.</Citation></Reference><Reference><Citation>Soare I-A, Ansari W, Nguyen JL, et al. Health-related quality of life in mild-to-moderate COVID-19 in the UK: a cross-sectional study from pre- to post-infection. Health Qual Life Outcomes. 2024;22(1):12. doi: 10.1186/s12955-024-02230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-024-02230-5</ArticleId><ArticleId IdType="pmc">PMC10826014</ArticleId><ArticleId IdType="pubmed">38287294</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison CJ, Davies B, Cooper E, et al. Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun. 2023;14(1):6588. doi: 10.1038/s41467-023-41879-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41879-2</ArticleId><ArticleId IdType="pmc">PMC10598213</ArticleId><ArticleId IdType="pubmed">37875536</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. National life tables: UK. 2018&#x2013;2020 (2024). https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables. Accessed 12 Jan 2024.</Citation></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7july2022. Accessed 17 Aug 2023.</Citation></Reference><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) latest insights: Hospitals. 2023; Updated 28/03/2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals#hospital-admissions-by-age. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>Office for National Statistics. Single year of age and average age of death of people whose death was due to or involved COVID-19. 2023; Updated 21/07/2023. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/singleyearofageandaverageageofdeathofpeoplewhosedeathwasduetoorinvolvedcovid19. Accessed 04 Aug 2023.</Citation></Reference><Reference><Citation>Baguelin M, Flasche S, Camacho A, et al. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013;10(10):e1001527. doi: 10.1371/journal.pmed.1001527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001527</ArticleId><ArticleId IdType="pmc">PMC3793005</ArticleId><ArticleId IdType="pubmed">24115913</ArticleId></ArticleIdList></Reference><Reference><Citation>RDocumentation.org. optim: General-purpose Optimization. 2023. https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/optim. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>MacIntyre CR, Costantino V, Trent M. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine. 2022;40(17):2506&#x2013;2513. doi: 10.1016/j.vaccine.2021.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.042</ArticleId><ArticleId IdType="pmc">PMC8064825</ArticleId><ArticleId IdType="pubmed">33958223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira LS, de Almeida GB, Borges ME, et al. Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil. Vaccine. 2022;40(46):6616&#x2013;6624. doi: 10.1016/j.vaccine.2022.09.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.09.082</ArticleId><ArticleId IdType="pmc">PMC9527216</ArticleId><ArticleId IdType="pubmed">36210250</ArticleId></ArticleIdList></Reference><Reference><Citation>LaJoie Z, Usherwood T, Sampath S, Srivastava V. A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior. Sci Rep. 2022;12(1):20377. doi: 10.1038/s41598-022-24967-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-24967-z</ArticleId><ArticleId IdType="pmc">PMC9701759</ArticleId><ArticleId IdType="pubmed">36437375</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak HY, Dai T, Tang CS. Managing two-dose COVID-19 vaccine rollouts with limited supply: operations strategies for distributing time-sensitive resources. Prod Oper Manag. 2022. 10.1111/poms.13862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538244</ArticleId><ArticleId IdType="pubmed">36246547</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? Sci Adv. 2020;7(6):eabf1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128110</ArticleId><ArticleId IdType="pubmed">33536223</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi R, Ott M. SARS-CoV-2&#xa0;hybrid immunity: silver bullet or silver lining? Nat Rev Immunol. 2022;22(10):591&#x2013;592. doi: 10.1038/s41577-022-00771-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00771-8</ArticleId><ArticleId IdType="pmc">PMC9362961</ArticleId><ArticleId IdType="pubmed">35945353</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Infectious Diseases Why hybrid immunity is so triggering. Lancet Infect Dis. 2022;22(12):1649. doi: 10.1016/S1473-3099(22)00746-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00746-0</ArticleId><ArticleId IdType="pmc">PMC9648977</ArticleId><ArticleId IdType="pubmed">36372089</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi RK, Chen IP, Ma T, et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022;607(7918):351&#x2013;355. doi: 10.1038/s41586-022-04865-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04865-0</ArticleId><ArticleId IdType="pmc">PMC9279157</ArticleId><ArticleId IdType="pubmed">35584773</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Guzman PN, Knock E, Imai N, et al. Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. Nat Commun. 2023;14(1):4279. doi: 10.1038/s41467-023-39661-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39661-5</ArticleId><ArticleId IdType="pmc">PMC10352350</ArticleId><ArticleId IdType="pubmed">37460537</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnitzler L, Janssen LMM, Evers SMAA, et al. The broader societal impacts of COVID-19 and the growing importance of capturing these in health economic analyses. Int J Technol Assess Health Care. 2021;37(1):e43. doi: 10.1017/S0266462321000155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462321000155</ArticleId><ArticleId IdType="pubmed">33686927</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK. New vaccine marketing campaign urges millions to boost their immunity this winter. 2022; Updated 23/10/2022. https://www.gov.uk/government/news/new-vaccine-marketing-campaign-urges-millions-to-boost-their-immunity-this-winter. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>Barnard RC, Davies NG, Munday JD, et al. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. Nat Commun. 2022;13(1):4879. doi: 10.1038/s41467-022-32404-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32404-y</ArticleId><ArticleId IdType="pmc">PMC9389516</ArticleId><ArticleId IdType="pubmed">35986002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan AB, Doohan P, Wu SL, et al. Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach. Nat Commun. 2023;14(1):4325. doi: 10.1038/s41467-023-39736-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39736-3</ArticleId><ArticleId IdType="pmc">PMC10356855</ArticleId><ArticleId IdType="pubmed">37468463</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Social Care. JCVI statement on the COVID-19 vaccination programme for autumn 2023, 26 May&#xa0;2023. 2023. https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-advice-26-may-2023/jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-26-may-2023. Accessed 17 Aug 2023.</Citation></Reference><Reference><Citation>Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371(6532):916&#x2013;921. doi: 10.1126/science.abe6959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe6959</ArticleId><ArticleId IdType="pmc">PMC7963218</ArticleId><ArticleId IdType="pubmed">33479118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick MC, Galvani AP. Optimizing age-specific vaccination. Science. 2021;371(6532):890&#x2013;891. doi: 10.1126/science.abg2334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg2334</ArticleId><ArticleId IdType="pubmed">33479122</ArticleId></ArticleIdList></Reference><Reference><Citation>The UK government needs to expand covid-19 vaccination this winter. BMJ. 2023;382:p2006.</Citation><ArticleIdList><ArticleId IdType="pubmed">37652534</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M, Sun X, Moran MM, et al. Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients. J Patient Rep Outcomes. 2022;6(1):123. doi: 10.1186/s41687-022-00528-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-022-00528-w</ArticleId><ArticleId IdType="pmc">PMC9722994</ArticleId><ArticleId IdType="pubmed">36469198</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaghoubi M, Salimi M, Meskarpour-Amiri M. Systematic review of productivity loss among healthcare workers due to Covid-19. Int J Health Plann Manage. 2022;37(1):94&#x2013;111. doi: 10.1002/hpm.3351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hpm.3351</ArticleId><ArticleId IdType="pmc">PMC8652830</ArticleId><ArticleId IdType="pubmed">34655098</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK. Coronavirus and the social impacts of 'long COVID' on people's lives in Great Britain: 7 April to 13 June 2021. 2021; Updated 21/07/2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronavirusandthesocialimpactsoflongcovidonpeopleslivesingreatbritain/7aprilto13june2021. Accessed 08 Nov 2023.</Citation></Reference><Reference><Citation>Tufts J, Guan N, Zemedikun DT, et al. The cost of primary care consultations associated with long COVID in non-hospitalised adults: a retrospective cohort study using UK primary care data. BMC Primary Care. 2023;24(1):245. doi: 10.1186/s12875-023-02196-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-023-02196-1</ArticleId><ArticleId IdType="pmc">PMC10662438</ArticleId><ArticleId IdType="pubmed">37986044</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. 2021; Updated 01/04/2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021. Accessed 08 Nov 2023.</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerksieck P, Ballouz T, Haile SR, et al. Post COVID-19 condition, work ability and occupational changes in a population-based cohort. The Lancet Regional Health &#x2013; Europe. 2023;31:100671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10287546</ArticleId><ArticleId IdType="pubmed">37366496</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderwick H. Is the NHS overwhelmed? BMJ. 2022;376:o51. doi: 10.1136/bmj.o51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o51</ArticleId><ArticleId IdType="pubmed">35017162</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Confederation. Latest urgent and emergency care situation report shows rising winter virus levels. 2023; Updated 07/12/2023. https://www.nhsconfed.org/news/latest-urgent-and-emergency-care-situation-report-shows-rising-winter-virus-levels. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>NHS England. COVID-19 Hospital Activity. 2023. https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>NHS Providers. NHS Winter Watch 2023/2024 Week&#xa0;1 27 November - 03 December. 2023. https://nhsproviders.org/nhs-winter-watch-202324/week-1#:~:text=Measures%20are%20in%20place%20to,remains%20concerningly%20high%20at%2094.4%25. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>O&#x2019;Dowd A. Hospital bed occupancy rates in England reach dangerously high levels. BMJ. 2021;374:n2079. doi: 10.1136/bmj.n2079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2079</ArticleId><ArticleId IdType="pubmed">34417251</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England. NHS sets out plans for winter with new measures to help speed up discharge for patients and improve care. 2023; Updated 27/07/2023. https://www.england.nhs.uk/2023/07/nhs-sets-out-plans-for-winter-with-new-measures-to-help-speed-up-discharge-for-patients-and-improve-care/. Accessed 09 Jan 2024.</Citation></Reference><Reference><Citation>GOV.UK. Press release: COVID-19 vaccines have prevented 7.2&#xa0;million infections and 27,000 deaths. 2021. https://www.gov.uk/government/news/covid-19-vaccines-have-prevented-7-2-million-infections-and-27-000-deaths. Accessed 09 Nov 2023.</Citation></Reference><Reference><Citation>GOV.UK. Appendix 1: UKHSA report estimating the number needed to vaccinate to prevent COVID-19&#xa0;hospitalisation for booster vaccination in autumn 2023 in England. 2023; Updated 05/10/2023. https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-advice-26-may-2023/appendix-1-ukhsa-report-estimating-the-number-needed-to-vaccinate-to-prevent-covid-19-hospitalisation-for-booster-vaccination-in-autumn-2023-in-engla. Accessed 23 Nov 2023.</Citation></Reference><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) latest insights: Hospitals. 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals#hospital-admissions-by-age. Accessed 08 Dec 2023.</Citation></Reference><Reference><Citation>Office for National Statistics. Single year of age and average age of death of people whose death was due to or involved coronavirus (COVID-19). 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/singleyearofageandaverageageofdeathofpeoplewhosedeathwasduetoorinvolvedcovid19. Accessed 08 Dec 2023.</Citation></Reference><Reference><Citation>Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: a systematic review and meta-analysis. Int Immunopharmacol. 2022;109:108906. doi: 10.1016/j.intimp.2022.108906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108906</ArticleId><ArticleId IdType="pmc">PMC9148928</ArticleId><ArticleId IdType="pubmed">35671640</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicines and Healthcare products regulatory agency. Coronavirus vaccine - summary of Yellow Card reporting. 2023. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed 17 Aug 2023.</Citation></Reference><Reference><Citation>NHS. About COVID-19 vaccination. 2023; Updated 21/03/2023. https://www.nhs.uk/conditions/covid-19/covid-19-vaccination/about-covid-19-vaccination/#:~:text=Find%20out%20more%20about%20the,19%20vaccine%20on%20GOV.UK. Accessed 07 Dec 2023.</Citation></Reference><Reference><Citation>GOV.UK. Coronavirus vaccine - summary of Yellow Card reporting. 2023; Updated 08/03/2023. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed 06 Dec 2023.</Citation></Reference><Reference><Citation>GOV.UK. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3 September 2022. 2022. https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-programme-for-autumn-2022-update-15-august-2022. Accessed 25 July 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>